ArticleCells2023
Intermittent Theta Burst Stimulation Improves Motor and Behavioral Dysfunction through Modulation of NMDA Receptor Subunit Composition in Experimental Model of Parkinson's Disease.
Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Accelerated Intermittent Theta-Burst Stimulation for the Treatment of Alcohol Use Disorder: A Randomized Sham-Controlled Study With Six-Month Follow-Up.CNS neuroscience & therapeutics · 2026Trial
- Intermittent Theta-Burst Stimulation for Depressive Symptoms in Parkinson Disease: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Intermittent theta-burst stimulation to enhance physical therapy in Parkinson's disease: The STEP-PD randomized trial.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Trial
- Clinical Effect on Cortical Reactivity of Theta Burst Versus High-Frequency Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease: A TMS-EEG Study.CNS neuroscience & therapeutics · 2025Trial
- Transcranial Magnetic Stimulation in Parkinson's Disease and Parkinsonian Syndromes: A Narrative Expert Review.Life (Basel, Switzerland) · 2026Review
- The applications of TMS in brain function assessment and treatment of mental disorders: a narrative review.Frontiers in psychiatry · 2026Review
- Prolonged intermittent theta burst stimulation enhances hippocampal plasticity via GluN2A-mediated signaling.Frontiers in aging neuroscience · 2026Article
- The immune system in Parkinson's disease: what we know so far.Brain : a journal of neurology · 2024Review
- Experimental Models to Study Immune Dysfunction in the Pathogenesis of Parkinson's Disease.International journal of molecular sciences · 2024Review
- Sustained Systemic Antioxidative Effects of Intermittent Theta Burst Stimulation beyond Neurodegeneration: Implications in Therapy in 6-Hydroxydopamine Model of Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2024Article
- Time dependent changes in protein expression induced by intermittent theta burst stimulation in a cell line.Frontiers in neurology · 2024Article
- Global research hotspots and trends of theta burst stimulation from 2004 to 2023: a bibliometric analysis.Frontiers in neurology · 2024Article
- Noninvasive Neuromodulation in Parkinson's Disease: Insights from Animal Models.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disorder characterized by the progressive degeneration of the dopaminergic system, leading to a variety of motor and nonmotor symptoms. The currently available symptomatic therapy loses efficacy over time, indicating the need for new therapeutic approaches. Repetitive transcranial magnetic stimulation (rTMS) has emerged as one of the potential candidates for PD therapy. Intermittent theta burst stimulation (iTBS), an excitatory protocol of rTMS, has been shown to be beneficial in several animal models of neurodegeneration, including PD. The aim of this study was to investigate the effects of prolonged iTBS on motor performance and behavior and the possible association with changes in the NMDAR subunit composition in the 6-hydroxydopamine (6-OHDA)-induced experimental model of PD. Two-month-old male Wistar rats were divided into four groups: controls, 6-OHDA rats, 6-OHDA + iTBS protocol (two times/day/three weeks) and the sham group. The therapeutic effect of iTBS was evaluated by examining motor coordination, balance, spontaneous forelimb use, exploratory behavior, anxiety-like, depressive/anhedonic-like behavior and short-term memory, histopathological changes and changes at the molecular level. We demonstrated the positive effects of iTBS at both motor and behavioral levels. In addition, the beneficial effects were reflected in reduced degeneration of dopaminergic neurons and a subsequent increase in the level of DA in the caudoputamen. Finally, iTBS altered protein expression and NMDAR subunit composition, suggesting a sustained effect. Applied early in the disease course, the iTBS protocol may be a promising candidate for early-stage PD therapy, affecting motor and nonmotor deficits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.